Coya Therapeutics plans open-label extension of Phase 2/3 ALSTARS trial of COYA 302 in ALS

By Public Technologies
  • Coya Therapeutics plans an open-label extension for its Phase 2/3 ALSTARS trial of COYA 302 in ALS.
  • No clinical results were reported; the extension will collect longer-term safety and efficacy information beyond the 48-week period.
  • Start expected in November 2026 as the first cohort completes treatment, driven by investigator and participant requests to continue dosing.
  • Resource shift delays a planned Phase 2 study of COYA 302 in frontotemporal dementia to 2027 from 2H 2026.
  • Cash runway guidance unchanged; existing cash expected to fund operations into the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014378134) on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.